OncoCyte Corp (NYSEAMERICAN:OCX) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 432,349 shares, a drop of 30.0% from the October 15th total of 617,468 shares. Approximately 2.4% of the shares of the stock are sold short. Based on an average daily volume of 63,931 shares, the days-to-cover ratio is presently 6.8 days.
NYSEAMERICAN OCX opened at $1.90 on Friday. OncoCyte has a twelve month low of $1.10 and a twelve month high of $6.45.
OncoCyte (NYSEAMERICAN:OCX) last released its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02).
A number of equities research analysts have weighed in on OCX shares. Zacks Investment Research downgraded OncoCyte from a “buy” rating to a “hold” rating in a report on Wednesday, July 25th. MED assumed coverage on OncoCyte in a report on Monday, October 29th. They set a “positive” rating on the stock.
COPYRIGHT VIOLATION NOTICE: “OncoCyte Corp (OCX) Short Interest Down 30.0% in October” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/11/10/oncocyte-corp-ocx-short-interest-down-30-0-in-october.html.
OncoCyte Company Profile
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Featured Story: Benefits of owning preferred stock
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.